Non-animal-based affinity technologies can do more than improve animal welfare. These technologies can ensure that antibody products meet higher research, diagnostic, and therapeutic standards.
Domain Therapeutics says its biosensor platform can assess a receptor’s signaling repertoire and help identify and characterize selective ligands in a rapid, simple, and homogenous assay.
Sponsored content brought to you by By Arvind Kothandaraman General Manager, Specialty Diagnostics, PerkinElmer Finding the right solution for your coronavirus testing needs can be a difficult...
As experts in genetically-engineered animal development and maintenance with large-scale animal breeding capacity, antibody discovery, and preclinical pharmacology services, Biocytogen provides seamless integrated antibody discovery services to the biomedical community for a true one-stop solution from target to IND application.
The Sanofi-GSK vaccine combines Sanofi’s S-protein COVID-19 antigen, which is based on recombinant DNA technology, and GSK’s pandemic AS03 adjuvant.
The companies plan over three years to develop treatments addressing three target genes associated with neurodevelopmental disorders, by upregulating the expression of key genes that are inadequately expressed in individuals with the disorders.
Annual flu vaccinations tends to be less effective in the elderly than it does in young people, because as we age our immune systems get weaker, so the response to vaccination isn’t as robust. Scientists at Cincinnati Children's Hospital have found that this immune system dampening may be due to active suppression by a group of immune cells known as Thf10 cells, which produce interleukin-10. The team’s results in mice suggest that it may be possible to boost vaccine effectiveness in the elderly by transiently managing Tfh 10 cells in a way that avoids disrupting the useful roles the cells play in fending off other types of disease.
Mouse tumor T cells produce immunosuppressive steroids, even though T cells from healthy mice do not. This observation prompted scientists to prevent the T cells from producing the steroids, either by removing a key steroid-producing gene, or by switching it off with a drug. Tumor growth was dramatically reduced, suggesting that steroidogenesis in T cells is a target for cancer immunotherapy.
In this GENcast, our guest will tell us more about HTS using 3D cell models and why they are so crucial for current drug discovery projects. Moreover, he will provide scientific insight into the 3D cell panel screening service—called OncoSignature™—which uses a library of 200 cell lines grown in 3D spheroids to provide a better understanding of candidate cancer therapeutics.
Please wait while you are redirected to the right page...